2 Information about liraglutide

Marketing authorisation

2.1 Liraglutide (Saxenda, Novo Nordisk) is indicated 'as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of ≥30 kg/m² (obese), or ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea'.

Dosage in the marketing authorisation

2.2 For full details of dose schedules, see the summary of product characteristics.


2.3 The list price of liraglutide (Saxenda) is £196.20 for 5 × 6 mg/ml 3‑ml (18 mg) pre-filled pens (excluding VAT; BNF online, accessed September 2020). The company has a commercial arrangement. This makes the Saxenda brand of liraglutide available to the NHS with a discount only if it is purchased through a secondary-care tier 3 weight management service. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)